Monoclonal proteins (antibodies) are made up of joined protein chains – 2 short light chains and 2 longer, heavy chains. In light chain amyloidosis, abnormal plasma cells make too many light chains.

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, �lanc� aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical com ...

TORONTO--(BUSINESS WIRE)--Paradox Immunotherapeutics (“Paradox”), a pharmaceutical company focused on the development of innovative antibody therapies ... light chain amyloidosis (AL ...

Broadly neutralizing antibodies (bNAbs), isolated from a ... pBR322-based IG-lambda expression vector. We also thank J. Mascola, the VRC, USA, for the donation of the PGT121 heavy- and light-chain ...

Its platform includes common light chain-focused antibody discovery ... The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.